CA2652074C - Substituted carboxamides as group 1 metabotropic receptor antagonists - Google Patents

Substituted carboxamides as group 1 metabotropic receptor antagonists Download PDF

Info

Publication number
CA2652074C
CA2652074C CA2652074A CA2652074A CA2652074C CA 2652074 C CA2652074 C CA 2652074C CA 2652074 A CA2652074 A CA 2652074A CA 2652074 A CA2652074 A CA 2652074A CA 2652074 C CA2652074 C CA 2652074C
Authority
CA
Canada
Prior art keywords
formula
compound
mmol
preparation
pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2652074A
Other languages
English (en)
French (fr)
Other versions
CA2652074A1 (en
Inventor
Ryan Thomas Backer
Matthew Joseph Fisher
Steven Lee Kuklish
Sean Patrick Hollinshead
Edward C. R. Smith
Kumiko Takeuchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CA2652074A1 publication Critical patent/CA2652074A1/en
Application granted granted Critical
Publication of CA2652074C publication Critical patent/CA2652074C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2652074A 2006-06-08 2007-06-07 Substituted carboxamides as group 1 metabotropic receptor antagonists Expired - Fee Related CA2652074C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81183906P 2006-06-08 2006-06-08
US60/811,839 2006-06-08
PCT/US2007/070572 WO2008103185A2 (en) 2006-06-08 2007-06-07 Substituted carboxamides as group i metabotropic receptor antagonists

Publications (2)

Publication Number Publication Date
CA2652074A1 CA2652074A1 (en) 2008-08-28
CA2652074C true CA2652074C (en) 2013-08-06

Family

ID=39673278

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2652074A Expired - Fee Related CA2652074C (en) 2006-06-08 2007-06-07 Substituted carboxamides as group 1 metabotropic receptor antagonists

Country Status (30)

Country Link
US (1) US7960419B2 (enExample)
EP (1) EP2076502B1 (enExample)
JP (1) JP5108878B2 (enExample)
KR (1) KR101051559B1 (enExample)
CN (1) CN101466691B (enExample)
AT (1) ATE509921T1 (enExample)
AU (1) AU2007347428B2 (enExample)
BR (1) BRPI0712862A2 (enExample)
CA (1) CA2652074C (enExample)
CR (1) CR10410A (enExample)
CY (1) CY1111588T1 (enExample)
DK (1) DK2076502T3 (enExample)
EA (1) EA014233B1 (enExample)
EC (1) ECSP088939A (enExample)
ES (1) ES2362949T3 (enExample)
HR (1) HRP20110436T1 (enExample)
IL (1) IL195632A (enExample)
MA (1) MA30620B1 (enExample)
MX (1) MX2008015485A (enExample)
MY (1) MY148084A (enExample)
NO (1) NO341474B1 (enExample)
NZ (1) NZ573352A (enExample)
PL (1) PL2076502T3 (enExample)
PT (1) PT2076502E (enExample)
RS (1) RS51818B (enExample)
SI (1) SI2076502T1 (enExample)
TN (1) TNSN08506A1 (enExample)
UA (1) UA95480C2 (enExample)
WO (1) WO2008103185A2 (enExample)
ZA (1) ZA200809111B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0804685D0 (en) 2008-03-13 2008-04-16 Univ Edinburgh Therapeutic compounds and their use
MX2010010781A (es) 2008-04-04 2010-12-14 Lilly Co Eli 3-indazolil-4-piridilisotiazoles.
EP2443113A1 (en) * 2009-06-15 2012-04-25 The University Of Edinburgh Amido-isothiazole compounds and their use as inhibitors of 11beta-hsd1 for the treatment of metabolic syndrome and related disorders
JP5779181B2 (ja) 2009-09-16 2015-09-16 ザ ユニバーシティ オブ エディンバラ （４−フェニル−ピペリジン−１−イル）−［５−（１ｈ−ピラゾール−４−イル）−チオフェン−３−イル］−メタノン化合物及びそれらの使用
EP2563780B1 (en) 2010-04-29 2015-05-06 The University Of Edinburgh 3,3-disubstituted-(8-aza-bicyclo[3.2.1]oct-8-yl)-[5-(1h-pyrazol-4-yl)-thiophen-3-yl]-methanones as inhibitors of 11(beta)-hsd1
DK2921489T3 (en) 2012-11-13 2017-10-16 Nissan Chemical Ind Ltd 2-pyridone-RELATED
AU2017329677A1 (en) 2016-09-23 2019-04-18 Bayer Aktiengesellschaft N 3 -cyclically substituted thienouraciles and use thereof
CN117567266B (zh) * 2023-11-07 2024-06-14 康龙化成手性医药技术(宁波)有限公司 一种制备2-甲基环丙羧酸的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL72091A0 (en) 1983-06-20 1984-10-31 Lilly Co Eli N'-substituted(3-aryl 5-isothiazolyl)urea derivatives
DE4328425A1 (de) 1993-08-24 1995-03-02 Basf Ag Acylamino-substituierte Isoxazol- bzw. Isothiazolderivate, Verfahren zu deren Herstellung und ihre Verwendung
DK124393D0 (da) 1993-11-03 1993-11-03 Lundbeck & Co As H Compounds
DE19542372A1 (de) * 1995-11-14 1997-05-15 Bayer Ag Acylierte 5-Aminoisothiazole
UA60365C2 (uk) * 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
JP3411262B2 (ja) * 1999-08-20 2003-05-26 萬有製薬株式会社 新規スピロ化合物
JP2005501073A (ja) * 2001-08-06 2005-01-13 フアルマシア・イタリア・エツセ・ピー・アー キナーゼ阻害薬活性を有するアミノイソオキサゾール誘導体
EP1667983A4 (en) * 2003-09-23 2010-07-21 Merck Sharp & Dohme PYRAZOL MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
WO2005113534A2 (en) * 2004-05-12 2005-12-01 Schering Corporation Cxcr1 and cxcr2 chemokine antagonists
BRPI0515571A (pt) * 2004-09-23 2008-07-29 Pfizer Prod Inc agonistas de receptor de trombopoetina

Also Published As

Publication number Publication date
EP2076502A2 (en) 2009-07-08
JP2009539874A (ja) 2009-11-19
MY148084A (en) 2013-02-28
CA2652074A1 (en) 2008-08-28
MX2008015485A (es) 2009-03-06
EA014233B1 (ru) 2010-10-29
PT2076502E (pt) 2011-06-07
RS51818B (sr) 2011-12-31
SI2076502T1 (sl) 2011-09-30
DK2076502T3 (da) 2011-07-25
KR101051559B1 (ko) 2011-07-22
ECSP088939A (es) 2009-01-30
IL195632A0 (en) 2009-09-01
TNSN08506A1 (en) 2010-04-14
HRP20110436T1 (hr) 2011-08-31
CR10410A (es) 2008-11-28
US20090182025A1 (en) 2009-07-16
EA200870516A1 (ru) 2009-06-30
NO341474B1 (no) 2017-11-27
AU2007347428A1 (en) 2008-08-28
CN101466691A (zh) 2009-06-24
EP2076502B1 (en) 2011-05-18
JP5108878B2 (ja) 2012-12-26
ES2362949T3 (es) 2011-07-15
WO2008103185A2 (en) 2008-08-28
PL2076502T3 (pl) 2011-09-30
WO2008103185A3 (en) 2008-10-30
ATE509921T1 (de) 2011-06-15
ZA200809111B (en) 2009-12-30
CY1111588T1 (el) 2015-10-07
NO20085028L (no) 2008-12-02
IL195632A (en) 2013-11-28
AU2007347428B2 (en) 2012-02-09
CN101466691B (zh) 2011-07-27
HK1131984A1 (en) 2010-02-12
BRPI0712862A2 (pt) 2012-12-18
KR20090008460A (ko) 2009-01-21
US7960419B2 (en) 2011-06-14
UA95480C2 (uk) 2011-08-10
NZ573352A (en) 2011-10-28
MA30620B1 (fr) 2009-08-03

Similar Documents

Publication Publication Date Title
CA2652074C (en) Substituted carboxamides as group 1 metabotropic receptor antagonists
US8710086B2 (en) Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods of use thereof
CN105120860B (zh) 组蛋白脱乙酰酶抑制剂
JP5670338B2 (ja) ミトコンドリアの膜透過性遷移の阻害剤として有用なアクリルアミド誘導体
CA2764425C (en) Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid
SI9210305A (en) Indole derivatives, processes for their preparation and medicaments containing them
KR20100093119A (ko) 신규한 ｎ-(2-아미노-페닐)-아미드 유도체
EP1268466A1 (en) Decahydro-isoquinolines
CA2877603A1 (en) Novel cholecystokinin receptor ligands
HK1131984B (en) Substituted carboxamides as group i metabotropic receptor antagonists
DE60000790T2 (de) [(2-substituierte-5-[3-thienyl)-benzyl]-[2-([2-isopropoxy-5-fluoro]-phenoxy)-ethyl]-amine, verfahren zu ihrer herstellung und ihre verwendung als medikamente
CN104844471A (zh) 一种作为dor受体拮抗剂的化合物
WO2018163077A1 (en) Indanyl compounds as voltage gated sodium channel modulators
WO2016205031A1 (en) Fluoropyridyl pyrazol compounds
TW201329060A (zh) 做為ｔｒｐｖ３調節劑的色原烷衍生物
HK1147750B (en) Amino arylsulfonamide compounds and their use as 5-ht6 ligands
HK1147750A1 (en) Amino arylsulfonamide compounds and their use as 5-ht6 ligands

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20180607